A Study to Evaluate KarXT Injection
Phase 1
48
about 2.1 years
18–55
8 sites in CA, FL, GA +3
What this study is about
Researchers are testing different doses of KarXT, a medication, to see how safe it is and what levels are reached in the body. The trial will last for about 772 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take KarXT
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of participants with adverse events (AEs), Number of participants with adverse events of special interest (AESIs), Number of participants with serious adverse events (SAEs)
Secondary: Apparent terminal phase half-life (T-HALF), Apparent total body clearance (CLT/F), Area under the plasma concentration-time curve from time zero to 672 hours (AUC(0-672)), Area under the plasma concentration-time curve from time zero to infinity (AUC(INF)), Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)), Maximum concentration (Cmax), Number of participants with AEs, Number of participants with SAEs
Psychiatry / Mental Health